McKesson stock steadies as oncology and specialty growth supports earnings outlook

McKesson stock reflects a business increasingly driven by oncology and specialty pharmaceuticals, with recent earnings showing solid revenue growth and expanding adjusted earnings per share that underpin the healthcare distributor's long term outlook.

McKesson Corporation (ISIN US58155Q1031) remains one of the largest healthcare services and pharmaceutical distribution companies in the United States, and McKesson stock continues to be influenced by the group’s ability to drive earnings growth from core distribution operations and higher margin oncology and specialty services. In its financial year ended 31 March 2024, McKesson reported substantial revenue and adjusted earnings growth according to its latest investor materials, underlining the scale of the company’s cash generation and its role within the pharmaceutical supply chain.

Revenue up double digits in fiscal 2024

According to McKesson’s published results for the fiscal year ended 31 March 2024, the company generated total revenue of approximately $289 billion, reflecting an increase of around 11% compared with the prior fiscal year’s revenue of roughly $260 billion as the business expanded in U.S. Pharmaceutical and Specialty Solutions and benefited from volume growth in key therapeutic areas. This double digit revenue increase illustrates how the company’s scale and focus on large national accounts, independent pharmacies, and health systems continues to translate into top line expansion.

Within this performance, McKesson reported that adjusted earnings per diluted share for fiscal 2024 were about $27.50, up roughly 9% from approximately $25.20 in fiscal 2023, supported by operating leverage, disciplined cost control, and the mix shift toward higher margin oncology and specialty services. The increase in adjusted EPS of more than $2.30 year on year is notable given the already high absolute level of profitability and demonstrates the company’s ability to convert revenue growth into shareholder earnings while navigating reimbursement dynamics and drug pricing changes.

McKesson also highlighted strong cash generation in fiscal 2024. Operating cash flow from continuing operations reached roughly $6.5 billion, compared with about $5.8 billion in fiscal 2023, an increase of around $0.7 billion. This rise in cash flow gave McKesson more flexibility to invest in technology platforms, oncology practice management, and data solutions while continuing to return cash to shareholders through share repurchases and dividends.

Segment trends and oncology focus

McKesson’s U.S. Pharmaceutical segment remained the largest revenue contributor in fiscal 2024, accounting for the majority of the group’s $289 billion sales. Segment revenue grew by a high single to low double digit percentage versus fiscal 2023, driven by increased volumes in branded, generic, and specialty drugs, higher demand associated with chronic disease management, and expanding relationships with biopharmaceutical manufacturers who rely on McKesson’s distribution and commercialization support.

Beyond core distribution, McKesson’s oncology and specialty businesses continued to gain importance. According to its fiscal 2024 commentary, the company reported double digit revenue growth in its oncology-focused operations, supported by an expanding network of U.S. Oncology practices, higher utilization of infused therapies, and increased uptake of complex specialty medications that require robust logistics and patient support. This growth in oncology revenue provided a meaningful contribution to overall margin stability, as specialty services typically carry higher operating margins than traditional wholesale drug distribution.

The Medical-Surgical Solutions and international operations segments added diversification, even though they represent a smaller share of total revenue. Medical-Surgical Solutions benefited from continued demand for medical supplies across physician offices, clinics, and surgery centers, contributing mid single digit revenue growth compared with fiscal 2023 driven by procedure volumes and ongoing needs for consumable products. International operations delivered more modest growth due to currency effects and differing market conditions, but they remained strategically important in supporting global manufacturer relationships.

McKesson’s management emphasized that data and analytics capabilities are increasingly woven into its operational model. The company continues to invest in technology that helps pharmacies and providers manage inventory, optimize ordering patterns, and meet regulatory requirements, which in turn strengthens long term customer relationships. These investments aim to support incremental revenue opportunities and help defend margins amid competitive pressures.

Guidance, margins, and capital returns

For fiscal 2025 (the year ending 31 March 2025), McKesson issued guidance indicating that adjusted earnings per diluted share could rise into the high twenties to low thirties range, suggesting continued mid to high single digit growth from the fiscal 2024 base of approximately $27.50. This guidance reflects expectations of ongoing revenue growth in U.S. Pharmaceutical distribution, further expansion in oncology and specialty, and disciplined cost management. The forecast also assumes that pricing and reimbursement conditions remain broadly in line with recent experience, although management noted that some variability is possible.

McKesson’s operating margin in fiscal 2024 remained relatively low on a consolidated basis given the nature of wholesale distribution, at around 2% on an operating income to revenue basis. However, the stability of this margin and the fact that adjusted operating profit grew roughly in line with revenue indicates that the company successfully maintained its spread between purchase and sale prices across large volumes of pharmaceuticals. Margin resilience is particularly important for McKesson stock, as investors monitor how distribution economics respond to generic drug price deflation and changes in brand drug reimbursement.

Capital allocation continues to play a central role in McKesson’s equity story. In fiscal 2024 the company repurchased a substantial amount of its own shares, reducing weighted average diluted share count and supporting the roughly 9% increase in adjusted EPS. As an illustration, McKesson’s share repurchases and dividend payments together returned more than $6 billion to shareholders during the year, funded by strong operating cash flow and a balanced approach to leverage. The company’s dividend, while modest relative to earnings, provides an additional return component alongside share price performance.

McKesson’s balance sheet remained manageable in fiscal 2024, with total debt below a level that would significantly constrain strategic flexibility. The combination of robust cash generation, relatively low capital intensity, and ongoing share repurchases means that changes in earnings guidance and capital return plans can have a noticeable effect on investor sentiment toward McKesson stock over time.

Oncology and specialty product footprint

McKesson’s oncology and specialty businesses center on supporting physician practices, health systems, and patients who rely on complex therapies. Through its U.S. Oncology Network and related initiatives, McKesson enables oncology clinics to access infused and oral oncology medications, manage reimbursement processes, and coordinate care. This network includes hundreds of locations and thousands of affiliated physicians, giving McKesson a significant presence in cancer care delivery across the United States.

In fiscal 2024, oncology related revenue grew at a double digit rate versus fiscal 2023, driven by higher patient volumes, expanded access to immunotherapies and targeted treatments, and increased use of supportive care drugs. This revenue growth outpaced the overall company rate of around 11%, reinforcing oncology’s role as a margin accretive segment. For McKesson stock, this means that changes in oncology volume trends, new therapy launches, or shifts in practice patterns can have a meaningful impact on medium term earnings expectations.

McKesson also plays a role in specialty pharmaceuticals beyond oncology, including therapies for autoimmune diseases, rare conditions, and chronic illnesses that require cold chain logistics and close coordination between manufacturers, payers, and providers. The company’s capabilities in specialty distribution and services position it as a key intermediary for these therapies, which often carry higher price points and generate more significant gross profit per unit than standard retail pharmacy drugs.

Technology and data solutions support McKesson’s oncology and specialty operations. Platforms that manage electronic health records, chemotherapy ordering, and patient scheduling help improve efficiency and care quality for oncology practices. Data analytics enable providers to understand treatment patterns and outcomes, while also supporting manufacturers’ post launch monitoring and commercialization strategies. These solutions create incremental revenue streams and deepen customer relationships, which can help sustain growth even as competition intensifies.

McKesson stock and market context

McKesson stock is listed on the New York Stock Exchange under the ticker symbol MCK and is included in the S&P 500 index, reflecting its status as a large U.S. healthcare company with substantial market capitalization. As of 30 June 2024, McKesson’s market capitalization stood at approximately $60 billion, based on prevailing share prices and shares outstanding, which places it among the larger constituents in the U.S. healthcare distribution and services space.

At that time, McKesson shares traded in a broad 52 week range between roughly $380 and $520, illustrating the volatility associated with changes in earnings expectations, interest rate movements, and broader equity market sentiment. A share price of around $480 as of 30 June 2024 sits closer to the upper end of this range, indicating that the market has generally rewarded the company’s execution and earnings delivery over the preceding year. Relative to the roughly $380 level observed around mid 2023, this represents an increase of about $100 per share, or roughly 26%, underscoring the positive share price trend.

McKesson’s valuation metrics, such as price to earnings based on the fiscal 2024 adjusted EPS of approximately $27.50, imply a forward looking multiple in the mid to high teens when compared with the share price around $480. This level balances expectations for continued growth in oncology and specialty operations with awareness of the cyclical and regulatory risks inherent in pharmaceutical distribution. Peer comparisons with other distributors and healthcare service companies suggest that McKesson’s valuation is broadly aligned with the sector, though differences in business mix and capital allocation strategies can cause divergence over time.

For investors, the interaction between McKesson’s earnings guidance, oncology and specialty growth, and share repurchase activity will likely remain central to the McKesson stock narrative. Strong execution against guidance, stable margins, and visible progress in oncology initiatives can support the share price, while unexpected changes in drug pricing or reimbursement frameworks could introduce volatility.

Stock price and listing details

As of 30 June 2024, McKesson stock closed at approximately $480 per share on the New York Stock Exchange, denominated in U.S. dollars. This price level reflects investor confidence in the company’s ability to grow adjusted EPS from the fiscal 2024 base of about $27.50 and to maintain its position as a key partner for pharmacies, hospitals, and oncology practices. The listing under the NYSE: MCK ticker provides liquidity and index participation, making the shares accessible to a wide range of institutional and retail investors.

McKesson stock key data

• Company: McKesson Corporation
• ISIN: US58155Q1031
• Ticker: NYSE: MCK
• Trading venue: New York Stock Exchange
• Price (as of 30 June 2024, 16:00 ET): 480 USD
• Market capitalization: 60,000,000,000 USD (as of 30 June 2024)
• Sector / Industry: Health Care / Health Care Distributors
• Index membership: S&P 500
• Next earnings date: 31 July 2024